Epoch Biotech, LLC STTR Phase I award

Department of Health and Human Services, through National Institutes of Health, awarded Epoch Biotech, LLC of Dover, MA $498,709 under the STTR program (Phase I), with work starting 2025-08-20 and running to 2027-08-19. It is the only SBIR or STTR award to Epoch Biotech, LLC in the last two years. Each figure links to the federal record.

The award

Want the whole picture on Epoch Biotech, LLC?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Epoch Biotech, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Epoch Biotech, LLC covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What it is for

Preclinical efficacy of an apoe targeted antibody for alzheimer's disease - abstract we propose to challenge alzheimer’s disease (ad) by modulating the interaction between apolipoprotein e (apoe) and glycosaminoglycans (

Funding actions on this award

Preclinical efficacy of an apoe targeted antibody for alzheimer's disease - abstract we propose to challenge alzheimer’s disease (ad) by modulating the interaction between apolipoprotein e (apoe) and glycosaminoglycans (gags) using therapeutic humanized antibodies. The founders of epoch biotech identified an individual that remained cognitively unimpaired until her seventies despite carrying a PRESENILIN-1 (PSEN1) mutation known to cause ad-related cognitive impairment at a median age of 44 years in the world’s largest population with autosomal dominant ad (adad) including over 1,200 PSEN1 mutation carriers. Clinical and positron emission tomography (PET) imaging studies of this subject showed extremely high amyloid but lower than expected for age tau burden and neurodegeneration. A comprehensive genetic analysis of this individual uncovered a homozygote rare variant in APOE3 (R136S, traditionally known as the christchurch variant) as the variant associated with the resistance to ad in this subject. Subsequently, our team and others have shown that the protective effect of the christchurch mutation is generalizable to the broader population of patients with the APOE4 risk variant. Gags have been suggested to promote aβ aggregation and neuronal uptake of extracellular tau; and apoe binding may be necessary for some of these effects. The team at schepens eye research institute of ...

From the federal award record.

More on Epoch Biotech, LLC

Epoch Biotech, LLC's funding history and team

Where this comes from

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.

Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.

All SBIR and STTR awards